Paradigm Biocapital Advisors LP
Q1 2022 13F-HR Holdings
Net value change ($000)
+28,021
(8.0%)
New positions
7
Sold out positions
6
Turnover %
39.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INCY | 18,618 | NEW |
| Sierra Oncology, Inc. | 14,396 | 139.4% |
| Horizon Therapeutics Public Ltd Co | 14,334 | NEW |
| UTHR | 13,570 | NEW |
| LEGN | 12,235 | 68.0% |
| ARVN | 11,011 | 49.9% |
| Global Blood Therapeutics, Inc. | 10,646 | 46.6% |
| IMCR | 10,329 | 224.7% |
| PRTA | 9,799 | NEW |
| ASND | 8,396 | 28.6% |
Top Reduces (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | -30,067 | -78.8% |
| ARENA PHARMACEUTICALS INC | -23,400 | -100.0% |
| Seagen Inc. | -15,566 | -100.0% |
| ARGX | -14,725 | -100.0% |
| ZNTL | -11,985 | -47.5% |
| INSM | -10,742 | -100.0% |
| GLPG | -9,252 | -100.0% |
| ENTA | -5,646 | -100.0% |
| VOR | -1,911 | -26.1% |
| Gracell Biotechnologies Inc. | -1,469 | -44.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|